Log In or Sign Up

Glioblastoma: Prognosis, Life Expectancy, and Survival Factors in Aggressive Brain Cancer

Laboratory microscope beside a histology slide and a sealed specimen container at a molecular analysis workstation.

Glioblastoma is one of the most aggressive brain tumors and represents a significant challenge in clinical practice due to its unfavorable prognosis and limited response to current therapies. Despite advances in treatment, the life expectancy for patients with glioblastoma remains short, with a median survival that rarely exceeds 15 months after initial diagnosis.

Diving Deeper into Prognosis and Survival

The prognosis of glioblastoma is influenced by multiple factors, including the extent of surgical resection, the presence of MGMT promoter methylation, and specific molecular characteristics of the tumor. Studies have shown that extensive surgical resection, removing more than 98% of the tumor volume, is associated with a significant improvement in survival [1]. Additionally, MGMT promoter methylation has been identified as an important predictor of better prognosis, providing an advantage in overall and progression-free survival [2].

The molecular characterization of glioblastoma has revealed genetic alterations that can influence prognosis. For example, mutations in the TERT promoter and PI3K-Akt-mTOR pathways are common and may offer opportunities for targeted therapies [3]. Furthermore, the expression of certain genes, such as CD40LG, has been associated with poorer prognosis, suggesting its potential as a therapeutic marker [4].

Conclusions

Despite advances in understanding the biology of glioblastoma, brain cancer survival remains a challenge. The integration of molecular and clinical data is crucial for improving the management of these patients. Identifying specific prognostic factors and developing personalized therapies could offer new hopes for improving survival in aggressive brain tumors like glioblastoma.

Referencias


Created 14/1/2025